Browsing by Subject "Therapy resistance"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Drug resistance and new therapies in colorectal cancer
    (Baishideng, 2018-09-14) Van der Jeught, Kevin; Xu, Han-Chen; Li, Yu-Jing; Lu, Xiong-Bin; Ji, Guang; Medical and Molecular Genetics, School of Medicine
    Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell dissemination has taken place. Chemo- and targeted therapies provide only a limited increase of overall survival for these patients. The major reason for clinical outcome finds its origin in therapy resistance. Escape mechanisms to both chemo- and targeted therapy remain the main culprits. Here, we evaluate major resistant mechanisms and elaborate on potential new therapies. Amongst promising therapies is α-amanitin antibody-drug conjugate targeting hemizygous p53 loss. It becomes clear that a dynamic interaction with the tumor microenvironment exists and that this dictates therapeutic outcome. In addition, CRC displays a limited response to checkpoint inhibitors, as only a minority of patients with microsatellite instable high tumors is susceptible. In this review, we highlight new developments with clinical potentials to augment responses to checkpoint inhibitors.